Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nicole Barberis

Allergy & Immunology Lakewood, CO Medical Doctor

NPI 1487093514 CMS profile 1386379

1746 Cole Blvd Ste 320, Lakewood, CO 80401

Open in the dashboard

General payments

$351,059

800 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nicole Barberis of Lakewood, CO is reported in the CMS Open Payments database as having received $351,059 across 800 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $124,658 215
2024 General $80,171 148
2023 General $82,458 177
2022 General $34,886 108
2021 General $16,722 53
2020 General $9,238 54
2019 General $2,926 45

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nicole Barberis
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Nicole Barberis were reported at $124,658. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Nicole Barberis Allergy & Immunology median Middle half National median
2019 $2,926 $594 $163–$1,512 $163
2020 $9,238 $426 $106–$1,233 $114
2021 $16,722 $638 $157–$1,708 $132
2022 $34,886 $790 $205–$1,961 $149
2023 $82,458 $852 $220–$2,147 $160
2024 $80,171 $865 $203–$2,267 $164
2025 $124,658 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Genzyme Corporation $235,739 332 payments
  2. Regeneron Healthcare Solutions, Inc. $82,411 180 payments
  3. AstraZeneca Pharmaceuticals LP $11,367 72 payments
  4. Novartis Pharmaceuticals Corporation $4,953 25 payments
  5. kaleo, Inc. $4,015 13 payments
  6. Sanofi US Services Inc. $2,660 1 payment
  7. Grifols USA, LLC $1,966 11 payments
  8. Genentech USA, Inc. $1,868 33 payments
  9. Grifols Shared Services North America, Inc. $1,328 1 payment
  10. Arcutis Biotherapeutics, Inc. $1,100 1 payment
  11. Other $3,652 131 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $201,470 86 payments
  2. Consulting Fee $91,934 34 payments
  3. Travel and Lodging $37,462 159 payments
  4. Food and Beverage $20,113 517 payments
  5. Education $80 4 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT Immunology $226,452 360 payments
  2. DUPIXENT Inflammation And Immunology $43,206 114 payments
  3. DUPIXENT Immunology And Inflammation $23,469 46 payments
  4. AUVI-Q $3,981 11 payments
  5. Xembify $3,204 6 payments
  6. AYVAKIT $2,795 4 payments
  7. Xolair $2,014 34 payments
  8. FASENRA $1,756 18 payments
  9. Zoryve $1,100 1 payment
  10. TEZSPIRE $791 15 payments
  11. Other $5,471 197 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

320

Median for Allergy/ Immunology: 449

Drug cost

$174,774

Median for Allergy/ Immunology: $169,700

Branded share of claims

54.7%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Syringe Dupilumab Brand 16 $70,663
Dupixent Pen Dupilumab Brand 14 $61,851
Symbicort Budesonide/Formoterol Fumarate Brand 44 $18,908
Breo Ellipta Fluticasone/Vilanterol Brand 18 $6,597
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 24 $6,522
Advair Diskus Fluticasone Propion/Salmeterol Brand 12 $4,127
Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate Brand 13 $2,401
Ipratropium Bromide Generic 46 $1,174
Ventolin Hfa Albuterol Sulfate Brand 11 $759
Albuterol Sulfate Hfa Albuterol Sulfate Brand 23 $668

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$69,000

Medicare's payments for the services billed

Medicare patients

158

Average age 72

Services billed

3,709

96 women, 62 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 47%
High blood pressure 46%
Osteoporosis 21%
Ischemic heart disease 18%
Cancer 17%
Chronic kidney disease 15%
Depression 15%
Diabetes 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
$69,910 30 —
FASENRA
$856 — —
XOLAIR
$232 — —
RUCONEST
$117 — —
TEZSPIRE
$78 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

800 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record